synflorix suspension for injection (prefilled syringe)
glaxosmithkline pte ltd - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d; diphtheria toxoid (dt) carrier protein; polysaccharide (ps); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae); tetanus toxoid (tt) carrier protein - injection, suspension - 1 μg ps1; 1.11-1.67 μg pd/dose - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d 1 μg ps1; 1.11-1.67 μg pd/dose; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d 1 μg ps14; 1.00-1.82 μg pd/dose; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid 3 μg ps18c; 5.45-10.00 μg tt/dose; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid 3 μg ps19f; 3.33-6.00 μg dt/dose; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d 1 μg ps23f; 0.39-0.74 μg pd/dose; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d 3 μg ps4; 3.33-6.67 μg pd/dose; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d 1 μg ps5; 0.67-1.25 μg pd/dose; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d 1 μg ps6b; 0.56-0.95 μg pd/dose; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d 1 μg ps7f; 0.87-1.43 μg pd/dose; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d 1 μg ps9v; 1.00-1.82 μg pd/dose; diphtheria toxoid (dt) carrier protein 3-6 μg dt/dose (total dt content); polysaccharide (ps) 16 μg/dose (total ps content); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae) 9-16 μg pd/dose (total pd content); tetanus toxoid (tt) carrier protein 5-10 μg/dose (total tt content)
synflorix vaccine suspension for injection 0.5ml pre-filled syringes
glaxosmithkline uk ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection
prevenar 13 vaccine suspension for injection 0.5ml pre-filled syringes
pfizer ltd - streptococcus pneumoniae capsular polysaccharide protein conjugate - suspension for injection
menactra- neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen, neisseria meningitidis gro
sanofi pasteur inc. - neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen (unii: re9a0h8oab) (neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen - unii:re9a0h8oab), neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen (unii: 2j57k2523t) (neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen - unii:2j57k2523t), neisseria meningitidis group y capsular polysaccharide diphtheria - neisseria meningitidis group a capsular polysaccharide diphtheria toxoid conjugate antigen 4 ug in 0.5 ml - menactra® , meningococcal (groups a, c, y and w-135) polysaccharide diphtheria toxoid conjugate vaccine, is indicated for active immunization to prevent invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, y and w-135. menactra is approved for use in individuals 9 months through 55 years of age. menactra does not prevent n meningitidis serogroup b disease. severe allergic reaction (eg, anaphylaxis) after a previous dose of a meningococcal capsular polysaccharide-, diphtheria toxoid- or crm197 -containing vaccine, or to any component of menactra [see description (11) ]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to menactra during pregnancy. to enroll in or obtain information about the registry, call sanofi pasteur at 1-800-822-2463. risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects an
nimenrix
pfizer pharmaceuticals israel ltd - neisseria meningitidis group a polysaccharide; neisseria meningitidis group c polysaccharide; neisseria meningitidis group w - 135 polysaccharide; neisseria meningitidis group y polysaccharide - powder and solvent for solution for injection - neisseria meningitidis group y polysaccharide 5 mcg; neisseria meningitidis group w - 135 polysaccharide 5 mcg; neisseria meningitidis group c polysaccharide 5 mcg; neisseria meningitidis group a polysaccharide 5 mcg - other meningococcal monovalent purified polysaccharides antigen - other meningococcal monovalent purified polysaccharides antigen - nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by neisseria meningitidis group a, c, w-135 and y.
pneumovax 23- pneumococcal vaccine polyvalent injection, solution
a-s medication solutions - streptococcus pneumoniae type 1 capsular polysaccharide antigen (unii: h9noi61uh1) (streptococcus pneumoniae type 1 capsular polysaccharide antigen - unii:h9noi61uh1), streptococcus pneumoniae type 2 capsular polysaccharide antigen (unii: e11p4f3x4s) (streptococcus pneumoniae type 2 capsular polysaccharide antigen - unii:e11p4f3x4s), streptococcus pneumoniae type 3 capsular polysaccharide antigen (unii: 4fvb62aff1) (streptococcus pneumoniae type 3 capsular polysaccharide antigen - unii:4fvb62aff1), strep - pneumovax® 23 is a vaccine indicated for active immunization for the prevention of pneumococcal disease caused by the 23 serotypes contained in the vaccine (1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19f, 19a, 20, 22f, 23f, and 33f). pneumovax 23 is approved for use in persons 50 years of age or older and persons aged ≥2 years who are at increased risk for pneumococcal disease. pneumovax 23 will not prevent disease caused by capsular types of pneumococcus other than those contained in the vaccine. do not administer pneumovax 23 to individuals with a history of anaphylactic/anaphylactoid or severe allergic reaction to any component of the vaccine. [see description (11).] risk summary all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. available human data from clinical trials of
pneumovax 23 -(5-dose) solution
merck canada inc - pneumococcal vaccine polyvalent - solution - 25mcg - pneumococcal vaccine polyvalent 25mcg - vaccines
pneumovax 23 solution for injection vaccine
merck sharp and dohme llc, united states - pneumococcal (streptococcus pneumoniae) polysaccharide (serotype 1, 2, 3, 4, 5, 6b, 7f, 8, 9n, 9v, 10a, 11a, 12f, 14, 15b, 17f, 18c, 19a, 19f, 20, 22f, 23f, 33f) - solution for injection - 50 µ/ml,
vaxneuvance 2 mcg/0.5 ml, 4 mcg/0.5 ml
مستودع أدوية أداتكو - adatco drug store - pneumococcal polysaccharide of serotypes 1,3,4,5,6a,7f,9v,14,18c,19a,19f,22f,23f,33f cojugated to crm197 carrier protein 2 mcg/0.5 ml, pneumococcal polysaccharide of serotype 6b cojugated to crm197 carrier protein 4 mcg/0.5 ml - 2 mcg/0.5 ml, 4 mcg/0.5 ml
vaxneuvance 2 mcg/0.5 ml, 4 mcg/0.5 ml
مستودع أدوية أداتكو - adatco drug store - pneumococcal polysaccharide of serotypes 1,3,4,5,6a,7f,9v,14,18c,19a,19f,22f,23f,33f cojugated to crm197 carrier protein 2 mcg/0.5 ml, pneumococcal polysaccharide of serotype 6b cojugated to crm197 carrier protein 4 mcg/0.5 ml - 2 mcg/0.5 ml, 4 mcg/0.5 ml